vs

Side-by-side financial comparison of EZCORP INC (EZPW) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.

EZCORP INC is the larger business by last-quarter revenue ($382.0M vs $281.3M, roughly 1.4× Guardant Health, Inc.). EZCORP INC runs the higher net margin — 11.6% vs -45.7%, a 57.3% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 19.3%). EZCORP INC produced more free cash flow last quarter ($31.7M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 15.6%).

EZCORP, Inc. is an American pawn shop operator based in Austin, Texas which provides services across the United States and Latin America. It is a publicly traded company listed on the NASDAQ stock exchange and is the second largest pawn shop operator in the U.S. after Cash America International.

Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.

EZPW vs GH — Head-to-Head

Bigger by revenue
EZPW
EZPW
1.4× larger
EZPW
$382.0M
$281.3M
GH
Growing faster (revenue YoY)
GH
GH
+20.1% gap
GH
39.4%
19.3%
EZPW
Higher net margin
EZPW
EZPW
57.3% more per $
EZPW
11.6%
-45.7%
GH
More free cash flow
EZPW
EZPW
$85.9M more FCF
EZPW
$31.7M
$-54.2M
GH
Faster 2-yr revenue CAGR
GH
GH
Annualised
GH
29.2%
15.6%
EZPW

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EZPW
EZPW
GH
GH
Revenue
$382.0M
$281.3M
Net Profit
$44.3M
$-128.5M
Gross Margin
58.4%
64.6%
Operating Margin
15.9%
-43.0%
Net Margin
11.6%
-45.7%
Revenue YoY
19.3%
39.4%
Net Profit YoY
42.8%
-15.8%
EPS (diluted)
$0.55
$-1.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EZPW
EZPW
GH
GH
Q4 25
$382.0M
$281.3M
Q3 25
$336.8M
$265.2M
Q2 25
$311.0M
$232.1M
Q1 25
$306.3M
$203.5M
Q4 24
$320.2M
$201.8M
Q3 24
$294.6M
$191.5M
Q2 24
$281.4M
$177.2M
Q1 24
$285.6M
$168.5M
Net Profit
EZPW
EZPW
GH
GH
Q4 25
$44.3M
$-128.5M
Q3 25
$26.7M
$-92.7M
Q2 25
$26.5M
$-99.9M
Q1 25
$25.4M
$-95.2M
Q4 24
$31.0M
$-111.0M
Q3 24
$15.2M
$-107.8M
Q2 24
$17.9M
$-102.6M
Q1 24
$21.5M
$-115.0M
Gross Margin
EZPW
EZPW
GH
GH
Q4 25
58.4%
64.6%
Q3 25
59.0%
64.7%
Q2 25
59.1%
65.0%
Q1 25
58.3%
63.3%
Q4 24
57.9%
61.6%
Q3 24
59.5%
61.1%
Q2 24
59.2%
59.1%
Q1 24
58.7%
61.2%
Operating Margin
EZPW
EZPW
GH
GH
Q4 25
15.9%
-43.0%
Q3 25
11.0%
-37.3%
Q2 25
11.6%
-45.9%
Q1 25
11.2%
-54.6%
Q4 24
13.1%
-62.4%
Q3 24
8.8%
-61.3%
Q2 24
7.9%
-56.8%
Q1 24
9.6%
-59.2%
Net Margin
EZPW
EZPW
GH
GH
Q4 25
11.6%
-45.7%
Q3 25
7.9%
-35.0%
Q2 25
8.5%
-43.0%
Q1 25
8.3%
-46.8%
Q4 24
9.7%
-55.0%
Q3 24
5.2%
-56.3%
Q2 24
6.4%
-57.9%
Q1 24
7.5%
-68.2%
EPS (diluted)
EZPW
EZPW
GH
GH
Q4 25
$0.55
$-1.01
Q3 25
$0.35
$-0.74
Q2 25
$0.34
$-0.80
Q1 25
$0.33
$-0.77
Q4 24
$0.40
$-0.90
Q3 24
$0.20
$-0.88
Q2 24
$0.25
$-0.84
Q1 24
$0.29
$-0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EZPW
EZPW
GH
GH
Cash + ST InvestmentsLiquidity on hand
$465.9M
$378.2M
Total DebtLower is stronger
$518.6M
$1.5B
Stockholders' EquityBook value
$1.1B
$-99.3M
Total Assets
$2.0B
$2.0B
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EZPW
EZPW
GH
GH
Q4 25
$465.9M
$378.2M
Q3 25
$469.5M
$580.0M
Q2 25
$472.1M
$629.1M
Q1 25
$505.2M
$698.6M
Q4 24
$174.5M
$525.5M
Q3 24
$170.5M
$585.0M
Q2 24
$218.0M
$933.7M
Q1 24
$229.1M
$1.0B
Total Debt
EZPW
EZPW
GH
GH
Q4 25
$518.6M
$1.5B
Q3 25
$518.1M
$1.1B
Q2 25
$517.6M
$1.1B
Q1 25
$620.5M
$1.1B
Q4 24
$327.7M
$1.1B
Q3 24
$327.3M
Q2 24
$361.3M
Q1 24
$360.9M
Stockholders' Equity
EZPW
EZPW
GH
GH
Q4 25
$1.1B
$-99.3M
Q3 25
$1.0B
$-354.5M
Q2 25
$990.1M
$-305.5M
Q1 25
$851.6M
$-250.8M
Q4 24
$823.9M
$-139.6M
Q3 24
$804.6M
$-60.1M
Q2 24
$801.5M
$-1.6M
Q1 24
$800.4M
$68.3M
Total Assets
EZPW
EZPW
GH
GH
Q4 25
$2.0B
$2.0B
Q3 25
$2.0B
$1.3B
Q2 25
$1.9B
$1.3B
Q1 25
$1.8B
$1.3B
Q4 24
$1.5B
$1.5B
Q3 24
$1.5B
$1.5B
Q2 24
$1.5B
$1.6B
Q1 24
$1.5B
$1.7B
Debt / Equity
EZPW
EZPW
GH
GH
Q4 25
0.48×
Q3 25
0.51×
Q2 25
0.52×
Q1 25
0.73×
Q4 24
0.40×
Q3 24
0.41×
Q2 24
0.45×
Q1 24
0.45×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EZPW
EZPW
GH
GH
Operating Cash FlowLast quarter
$39.1M
$-26.4M
Free Cash FlowOCF − Capex
$31.7M
$-54.2M
FCF MarginFCF / Revenue
8.3%
-19.3%
Capex IntensityCapex / Revenue
2.0%
9.9%
Cash ConversionOCF / Net Profit
0.88×
TTM Free Cash FlowTrailing 4 quarters
$121.7M
$-233.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EZPW
EZPW
GH
GH
Q4 25
$39.1M
$-26.4M
Q3 25
$51.3M
$-35.4M
Q2 25
$34.8M
$-60.3M
Q1 25
$36.9M
$-62.7M
Q4 24
$26.0M
$-64.5M
Q3 24
$43.3M
$-51.1M
Q2 24
$33.7M
$-94.0M
Q1 24
$15.1M
$-30.3M
Free Cash Flow
EZPW
EZPW
GH
GH
Q4 25
$31.7M
$-54.2M
Q3 25
$35.7M
$-45.8M
Q2 25
$25.7M
$-65.9M
Q1 25
$28.6M
$-67.1M
Q4 24
$20.4M
$-83.4M
Q3 24
$24.4M
$-55.3M
Q2 24
$30.5M
$-99.1M
Q1 24
$8.6M
$-37.2M
FCF Margin
EZPW
EZPW
GH
GH
Q4 25
8.3%
-19.3%
Q3 25
10.6%
-17.3%
Q2 25
8.3%
-28.4%
Q1 25
9.3%
-33.0%
Q4 24
6.4%
-41.3%
Q3 24
8.3%
-28.9%
Q2 24
10.8%
-55.9%
Q1 24
3.0%
-22.1%
Capex Intensity
EZPW
EZPW
GH
GH
Q4 25
2.0%
9.9%
Q3 25
4.6%
3.9%
Q2 25
2.9%
2.4%
Q1 25
2.7%
2.2%
Q4 24
1.8%
9.4%
Q3 24
6.4%
2.2%
Q2 24
1.1%
2.9%
Q1 24
2.3%
4.1%
Cash Conversion
EZPW
EZPW
GH
GH
Q4 25
0.88×
Q3 25
1.92×
Q2 25
1.31×
Q1 25
1.45×
Q4 24
0.84×
Q3 24
2.85×
Q2 24
1.88×
Q1 24
0.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EZPW
EZPW

Merchandise$210.1M55%
Pawn Service$131.9M35%
Jewelry Scrap$39.9M10%

GH
GH

Oncology$189.9M68%
Biopharma Data$54.0M19%
Screening$35.1M12%
Licensing Other$2.2M1%

Related Comparisons